IO-202 is under clinical development by Immune Onc Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IO-202’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IO-202 is under development for the treatment of relapsed or refractory acute myeloid leukemia, chronic myelomonocytic leukemia and solid tumors. The drug candidate acts by targeting LILRB4. It is administered through intravenous route.
Immune Onc Therapeutics overview
Immune Onc Therapeutics (Immune-Onc) is a cancer immunotherapy company. It discovers and develops new immunomodulatory approaches to cancer treatment. The company aims to translate unique scientific insights into the immune suppressive pathways and tumor microenvironment to develop first-in-class biotherapeutics. It identifies and utilizes antibodies targeting an immune inhibitory receptor for the treatment of acute myeloid leukemia (AML) and other cancers. Its pipeline product includes IO-202, for acute myeloid leukemia and other hematologic and solid tumors. Immune-Onc is headquartered in Palo Alto, California, the US.
For a complete picture of IO-202’s drug-specific PTSR and LoA scores, buy the report here.